Table.
Comorbidity with liver disease and liver dysfunction in patients with SARS-CoV-2 infection
| Patients with SARS-CoV-2 infection | Patients with pre-existing liver conditions | Patients with abnormal liver function | Notes | |
|---|---|---|---|---|
| Guan et al1 | 1099 | 23 (2·3%) | AST abnormal (22·2%), ALT abnormal (21·3%) | Elevated levels of AST were observed in 112 (18·2%) of 615 patients with non-severe disease and 56 (39·4%) of 142 patients with severe disease. Elevated levels of ALT were observed in 120 (19·8%) of patients with non-severe disease and 38 (28·1%) of 135 patients with severe disease. |
| Huang et al5 | 41 | 1 (2·0%) | 15 (31·0%) | Patients with severe disease had increased incidence of abnormal liver function. Elevation of AST level was observed in eight (62%) of 13 patients in the ICU compared with seven (25%) 25 patients who did not require care in the ICU. |
| Chen et al6 | 99 | NA | 43 (43·0%) | One patient with severe liver function damage. |
| Wang et al7 | 138 | 4 (2·9%) | NA | .. |
| Shi et al8 | 81 | 7 (8·6%) | 43 (53·1%) | Patients who had a diagnosis of COVID-19 confirmed by CT scan while in the subclinical phase had significantly lower incidence of AST abnormality than did patients diagnosed after the onset of symptoms. |
| Xu et al9 | 62 | 7 (11·0%) | 10 (16·1%) | .. |
| Yang et al10 | 52 | NA | 15 (29·0%) | No difference for the incidences of abnormal liver function between survivors (30%) and non-survivors (28%). |
| Our data (unpublished) | 56 | 2 (3·6%) | 16 (28·6%) | One fatal case, with evaluated liver injury.13 |
AST= aspartate aminotransferase. ALT= alanine aminotransferase. ICU=intensive care unit.